Tomas Simunek
Hradec Kralove, KR, Czech Republic
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications
Daunorubicin and its hydroxy metabolite in cardiomyocytes: insights into cellular kinetics, toxicity, DNA damage, and dexrazoxane-induced cardioprotection.
Journal: Archives of toxicology
Published: February 27, 2025
Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage.
Journal: Toxicological sciences : an official journal of the Society of Toxicology
Published: January 30, 2024
Hydrophobicity-enhanced ferritin nanoparticles for efficient encapsulation and targeted delivery of hydrophobic drugs to tumor cells.
Journal: Protein science : a publication of the Protein Society
Published: July 25, 2023
Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine.
Journal: Scientific reports
Published: November 02, 2021
Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
Journal: Circulation. Heart failure
Published: September 23, 2021
Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up.
Journal: Clinical science (London, England : 1979)
Published: August 26, 2021
Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo.
Journal: Clinical science (London, England : 1979)
Published: March 30, 2021
Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions.
Journal: Journal of medicinal chemistry
Published: March 22, 2021
Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
Journal: Scientific reports
Published: June 26, 2020
Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity.
Journal: The Journal of pharmacology and experimental therapeutics
Published: December 19, 2019
Binding of an amphiphilic phthalocyanine to pre-formed liposomes confers light-triggered cargo release.
Journal: Journal of materials chemistry. B
Published: April 16, 2019
Last Updated: 09/26/2026